The invention relates to a drug delivery system for contraception including a steroidal estrogenic compound, a steroidal progestogenic compound or a combination thereof for the purposes of contraception in a subject, and provides for an ultra-low dose delivery of a steroidal estrogenic compound which minimizes or eliminates a burst release effect. The invention also relates to a method of contraception using the drug delivery system and method of manufacturing the drug delivery system.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/566 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes non substitués en position 17 bêta par un atome de carbone, p. ex. œstrane, œstradiol ayant un groupe oxo en position 17, p. ex. œstrone
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Biological preparations for the treatment of eye conditions, namely, to slow down loss of eye sight due to wet age macular degeneration (wet AMD), diabetic macular edema (DME) and retinal vein occlusion (RVO); Biological preparations for the treatment of eye diseases; Biological preparations for use in intravitreal medicinal therapy; Pharmaceutical preparations for the treatment of wet AMD, DME and RVO; Pharmaceutical preparations for the treatment of eye diseases; Pharmaceutical preparations for slowing the growth of blood vessels in the eye, namely, anti-VEGF intravitreal injections; Pharmaceutical preparations for slowing down blindness due to proliferation of blood vessels in the eye
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Biological preparations for the treatment of eye conditions, namely, to slow down loss of eye sight due to wet age macular degeneration (wet AMD), diabetic macular edema (DME) and retinal vein occlusion (RVO); Biological preparations for the treatment of eye diseases; Biological preparations for use in intravitreal medicinal therapy; Pharmaceutical preparations for the treatment of wet AMD, DME and RVO; Pharmaceutical preparations for the treatment of eye diseases; Pharmaceutical preparations for slowing the growth of blood vessels in the eye, namely, anti-VEGF intravitreal injections; Pharmaceutical preparations for slowing down blindness due to proliferation of blood vessels in the eye
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Biological preparations for intravitreal injection to slow down loss of eye sight due to wet age macular degeneration (wet AMD), diabetic macular edema (DME) and retinal vein occlusion (RVO) and other related eye diseases; biological preparations for use in intravitreal therapy; pharmaceutical preparations for the treatment of wet AMD, DME, RVO and other related eye diseases; anti-VEGF intravitreal injections, pharmaceutical preparations for slowing down blindness due to proliferation of blood vessels in the eye.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Biological preparations for intravitreal injection to slow down loss of eye sight due to wet age macular degeneration (wet AMD), diabetic macular edema (DME) and retinal vein occlusion (RVO) and other related eye diseases; biological preparations for use in intravitreal therapy; pharmaceutical preparations for the treatment of wet AMD, DME, RVO and other related eye diseases; anti-VEGF intravitreal injections, pharmaceutical preparations for slowing down blindness due to proliferation of blood vessels in the eye.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Biological preparations for intravitreal injection to slow down loss of eye sight due to wet age macular degeneration (wet AMD), diabetic macular edema (DME) and retinal vein occlusion (RVO) and other related eye diseases; biological preparations for use in intravitreal therapy; pharmaceutical preparations for the treatment of wet AMD, DME, RVO and other related eye diseases; anti-VEGF intravitreal injections, pharmaceutical preparations for slowing down blindness due to proliferation of blood vessels in the eye.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Biological preparations for intravitreal injection to slow down loss of eye sight due to wet age macular degeneration (wet AMD), diabetic macular edema (DME) and retinal vein occlusion (RVO) and other related eye diseases; biological preparations for use in intravitreal therapy; pharmaceutical preparations for the treatment of wet AMD, DME, RVO and other related eye diseases; anti-VEGF intravitreal injections, pharmaceutical preparations for slowing down blindness due to proliferation of blood vessels in the eye.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
biological preparations and medications for the treatment of rheumatoid arthritis; pharmaceutical preparations and medications for the treatment of rheumatoid arthritis; biological preparations and medications for treating human immune diseases and conditions; pharmaceutical preparations and medications for treating human immune diseases and conditions
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
biological preparations and medications for the treatment of cancer; biological preparations for use in chemotherapy; pharmaceutical preparations and medications for the treatment of cancer; pharmaceutical preparations for use in chemotherapy; anti-cancer preparations; pharmaceutical preparations for use in stimulating white blood cell production
15.
DRUG DELIVERY SYSTEM FOR ULTRA-LOW DOSE ESTROGEN COMBINATIONS AND METHODS AND USES THEREOF
A61K 31/56 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes
A61K 31/565 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes non substitués en position 17 bêta par un atome de carbone, p. ex. œstrane, œstradiol
The invention relates to a drug delivery system for contraception including a steroidal estrogenic compound, a steroidal progestogenic compound or a combination thereof for the purposes of contraception in a subject, and provides for an ultra-low dose delivery of a steroidal estrogenic compound which minimizes or eliminates a burst release effect. The invention also relates to a method of contraception using the drug delivery system and method of manufacturing the drug delivery system.
A61K 31/565 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes non substitués en position 17 bêta par un atome de carbone, p. ex. œstrane, œstradiol
A61K 31/56 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes
A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
17.
DRUG DELIVERY SYSTEM FOR ULTRA-LOW DOSE ESTROGEN COMBINATIONS AND METHODS AND USES THEREOF
The invention relates to a drug delivery system for contraception including a steroidal estrogenic compound, a steroidal progestogenic compound or a combination thereof for the purposes of contraception in a subject, and provides for an ultra-low dose delivery of a steroidal estrogenic compound which minimizes or eliminates a burst release effect. The invention also relates to a method of contraception using the drug delivery system and method of manufacturing the drug delivery system.
A61K 31/566 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes non substitués en position 17 bêta par un atome de carbone, p. ex. œstrane, œstradiol ayant un groupe oxo en position 17, p. ex. œstrone
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
There is provided a dose counter assembly for use with a medicament dispenser, the dose counter assembly comprising: a) a units dose display means comprising a first count indicia and one or more driver teeth; b) a tens dose display means comprising a second count indicia; and c) a driver, wherein the first count indicia and second count indicia align at a common viewing area to collectively display a count sequence.
The application provides an applicator (1) for insertion of drug delivery device for subdermal administration of contraceptive or hormone replacement therapy comprising a housing (2), a needle (11), a pushrod (8), a needle guiding means (6), a protective cover (5) and an actuator (10). The applicator comprises a mechanism wherein needle is crimped such that it help to secure the implant inside the needle. Further, the application provides a mechanism wherein implant is loaded into the applicator through a slot (26) present in the needle at an angle perpendicular to the longitudinal axis of the needle.
A61M 37/00 - Autres appareils pour introduire des agents dans le corpsPercutanisation, c.-à-d. introduction de médicaments dans le corps par diffusion à travers la peau
The application provides an applicator (1) for insertion of drug delivery device for subdermal administration of contraceptive or hormone replacement therapy comprising a housing (2), a needle (11), a pushrod (8), a needle guiding means (6), a protective cover (5) and an actuator (10). The applicator comprises a mechanism wherein needle is crimped such that it help to secure the implant inside the needle. Further, the application provides a mechanism wherein implant is loaded into the applicator through a slot (26) present in the needle at an angle perpendicular to the longitudinal axis of the needle.
A61M 37/00 - Autres appareils pour introduire des agents dans le corpsPercutanisation, c.-à-d. introduction de médicaments dans le corps par diffusion à travers la peau
The present invention provides an applicator for insertion of drug delivery device for subdermal administration of contraceptive or hormone replacement therapy comprising a housing, a needle, a pushrod, a needle guiding means, a protective cover and an actuator. The applicator comprises a mechanism wherein needle is crimped such that it help to secure the implant inside the needle. Further, the invention provides a mechanism wherein implant is loaded into the applicator through a slot present in the needle at an angle perpendicular to the longitudinal axis of the needle.
A61M 5/32 - AiguillesParties constitutives des aiguilles relatives au raccordement de celles-ci à la seringue ou au manchonAccessoires pour introduire l'aiguille dans le corps ou l'y maintenirDispositifs pour la protection des aiguilles
A61M 5/46 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaireAccessoires à cet effet, p. ex. dispositifs de remplissage ou de nettoyage, appuis-bras avec des moyens pour commander la profondeur de pénétration
The invention of the present disclosure relates to a medicament dispenser for dispensing medicament from a plurality of elongate form medicament carriers, the dispenser comprising a dispensing mechanism for dispensing the medicament held within the dispenser, wherein the dispensing mechanism is capable of independently advancing each medicament carrier held within the dispenser, the dispensing mechanism comprising a driver, a carrier engagement for each medicament carrier for individually advancing the medicament dose portions thereof, an advancer for each carrier engagement, a flow director capable of dispensing a medicament dose from a plurality of medicament carriers, and a cover for the medicament access body operating as a component of the dispenser actuation mechanism.
The invention described herein provides new combination products for the cyclical provision of a methylcobalamin compound and a steroid compound in a dosing regimen wherein the total amount of methylcobalamin administered during any one treatment cycle does not exceed 35 mcg. More specifically, the combination products described in this disclosure promote the prevention or treatment of a vitamin B12 deficiency, support the replenishment and or maintenance of healthy blood cell levels, or both, particularly in those experiencing a periodic physiological challenge which may compromise vitamin B12 status or result in an increased requirement for vitamin B12, such as the monthly blood loss experienced by a reproductively cycling human female.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
Produits et services
(1) Inhalers filled with pharmaceutical preparations for the treatment of respiratory ailments;
(2) Inhalers used for the treatment of respiratory ailments;
28.
Dose Feedback Mechanisms and Assemblies for User Feedback
The present disclosure relates to a medicament dispenser for dispensing medicament. The dispenser may be for use in dispensing medicament in a liquid, pressurized aerosol, pre-filled container and in any medicament dispenser where dose related feedback is required. Mechanisms and assemblies provide dose related feedback to the user of the medicament dispenser and the physical interfaces and attributes associated with providing such feedback. The present disclosure also relates to dose feedback assemblies that can be adapted to various form factors, various individual components and elements of the container-closure system, and/or various target user interfaces. The dispenser is suited for dispensing propellant based pressurized inhalation aerosols for oral and/or nasal delivery; aqueous or non-aqueous systems for oral and/or nasal delivery; liquid dispensers for nasal delivery, multi-dose pre-filled syringes or pens; or dispensers for intra-muscular or subcutaneous delivery and powders for pulmonary administration and tablets, capsules, pellets or agglomerates for oral administration. The dispenser may dispense a propellant based pressurized inhalation aerosol comprising one or more active pharmaceutical ingredient(s) (API) and optionally, one or more propellant, cosolvent, solubilizer, emulsifier, surfactant, salt, acid and micronized or non-micronized pharmaceutically acceptable carrier(s) and/or excipient(s), wherein the dispensing process includes a press and breathe type or breath actuated or other multi-step operation medicament dispensers.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Pharmaceuticals, medical and veterinary preparations; sanitary preparations for medical purposes; dietetic food and substances adapted for medical or veterinary use, food for babies; dietary supplements for human beings and animals; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
A61K 31/565 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes non substitués en position 17 bêta par un atome de carbone, p. ex. œstrane, œstradiol
Method of treating or preventing trichomoniasis or T. vaginalis infection in a subject in need thereof, the method involving administering to the subject a therapeutically effective amount of secnidazole or a pharmaceutically acceptable salt in a microgranule formulation, wherein the microgranule formulation comprises a plurality of microgranules. The subject can also have bacterial vaginosis, is HIV-positive, and/or is suffering with metronidazole-resistant trichomoniasis and/or tinidazole-resistant trichomoniasis. The subject can also be a sexual partner of a person with trichomoniasis. The microgranule formulation can also be administered with paromomycin, tinidazole, metronidazole, boric acid or a combination thereof. Pharmaceutical compositions and uses for treating or preventing trichomoniasis or T. vaginalis infection in a subject in need thereof are also contemplated herein.
A61K 31/565 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes non substitués en position 17 bêta par un atome de carbone, p. ex. œstrane, œstradiol
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Pharmaceuticals, medical and veterinary preparations; sanitary preparations for medical purposes; dietetic food and substances adapted for medical or veterinary use, food for babies; dietary supplements for human beings and animals; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
There is provided a dose counter assembly for use with a medicament dispenser, the dose counter assembly comprising: a) a units dose display means comprising a first count indicia and one or more driver teeth; b) a tens dose display means comprising a second count indicia; and c) a driver, wherein the first count indicia and second count indicia align at a common viewing area to collectively display a count sequence.
There is provided a dose counter assembly for use with a medicament dispenser, the dose counter assembly comprising: a) a units dose display means comprising a first count indicia and one or more driver teeth; b) a tens dose display means comprising a second count indicia; and c) a driver, wherein the first count indicia and second count indicia align at a common viewing area to collectively display a count sequence.
The invention of the present disclosure relates to a medicament dispenser for dispensing medicament from a plurality of elongate form medicament carriers, the dispenser comprising a dispensing mechanism for dispensing the medicament held within the dispenser, wherein the dispensing mechanism is capable of independently advancing each medicament carrier held within the dispenser, the dispensing mechanism comprising a driver, a carrier engagement for each medicament carrier for individually advancing the medicament dose portions thereof, an advancer for each carrier engagement, a flow director capable of dispensing a medicament dose from a plurality of medicament carriers, and a cover for the medicament access body operating as a component of the dispenser actuation mechanism.
The invention of the present disclosure relates to a medicament dispenser for dispensing medicament from a plurality of elongate form medicament carriers, the dispenser comprising a dispensing mechanism for dispensing the medicament held within the dispenser, wherein the dispensing mechanism is capable of independently advancing each medicament carrier held within the dispenser, the dispensing mechanism comprising a driver, a carrier engagement for each medicament carrier for individually advancing the medicament dose portions thereof, an advancer for each carrier engagement, a flow director capable of dispensing a medicament dose from a plurality of medicament carriers, and a cover for the medicament access body operating as a component of the dispenser actuation mechanism.
The invention described herein provides new methods and compositions for the cyclical provision of a vitamin B12 compound in a dosing regimen wherein the total amount of vitamin B12 administered during any one treatment cycle does not exceed 35 mcg. More specifically, the invention described in this disclosure promotes the prevention or treatment of a vitamin B12 deficiency, supports the replenishment and or maintenance of healthy blood cell levels, or both, particularly in those experiencing a periodic physiological challenge which may compromise vitamin B12 status or result in an increased requirement for vitamin B12, such as the monthly blood loss experienced by a reproductively cycling human female.
The invention described herein provides new methods and compositions for the cyclical provision of a vitamin B12 compound in a dosing regimen wherein the total amount of vitamin B12 administered during any one treatment cycle does not exceed 35 mcg. More specifically, the invention described in this disclosure promotes the prevention or treatment of a vitamin B12 deficiency, supports the replenishment and or maintenance of healthy blood cell levels, or both, particularly in those experiencing a periodic physiological challenge which may compromise vitamin B12 status or result in an increased requirement for vitamin B12, such as the monthly blood loss experienced by a reproductively cycling human female.
A61K 31/57 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone
A61K 31/566 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes non substitués en position 17 bêta par un atome de carbone, p. ex. œstrane, œstradiol ayant un groupe oxo en position 17, p. ex. œstrone
A medicament dispenser for dispensing medicament comprising: an assembly comprising: at least one peelable medicament carrier carrying multiple distinct medicament portions; a medicament carrier advancing mechanism; a flow channel; and a hinged cover for the flow channel.
A soft gelatin capsule composition for vaginal administration of secnidazole includes a therapeutically effective amount of secnidazole dispersed in a pharmaceutically acceptable carrier. The therapeutically effective amount of secnidazole is in a range of from about 1 mg to about 500 mg, or in a range of from about 1,000 mg to about 1,500 mg. The composition is used for treating diseases, including bacterial vaginosis or trichomoniasis.
New deuterated analogs of elagolix are provided. The novel deuterated elagolix analogs differ from the only previously disclosed deuterated elagolix analogs in structure based on the exclusion of deuterium at certain sites in the compounds and the inclusion of deuterium at other sites. Also provided are new formulations for deuterated elagolix compounds and methods of using such compounds and formulations in the modification of mammalian physiology and especially in the treatment and prevention of a number of diseases and disorders, including endometriosis-associated pain and uterine fibroid conditions.
C07D 239/46 - Plusieurs atomes d'oxygène, de soufre ou d'azote
A61K 31/513 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime ayant des groupes oxo liés directement à l'hétérocycle, p. ex. cytosine
A61P 15/00 - Médicaments pour le traitement des troubles génitaux ou sexuelsContraceptifs
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
44.
DOSE FEEDBACK MECHANISMS AND ASSEMBLIES FOR USER FEEDBACK
The present disclosure relates to a medicament dispenser for dispensing medicament. The dispenser may be for use in dispensing medicament in a liquid, pressurized aerosol, pre-filled container and in any medicament dispenser where dose related feedback is required. Mechanisms and assemblies provide dose related feedback to the user of the medicament dispenser and the physical interfaces and attributes associated with providing such feedback. The present disclosure also relates to dose feedback assemblies that can be adapted to various form factors, various individual components and elements of the container-closure system, and/or various target user interfaces. The dispenser is suited for dispensing propellant based pressurized inhalation aerosols for oral and/or nasal delivery; aqueous or non-aqueous systems for oral and/or nasal delivery; liquid dispensers for nasal delivery, multi-dose pre-filled syringes or pens; or dispensers for intra-muscular or subcutaneous delivery and powders for pulmonary administration and tablets, capsules, pellets or agglomerates for oral administration. The dispenser may dispense a propellant based pressurized inhalation aerosol comprising one or more active pharmaceutical ingredient(s)(API) and optionally, one or more propellant, cosolvent, solubilizer, emulsifier, surfactant, salt, acid and micronized or non-micronized pharmaceutically acceptable carrier(s) and/or excipient(s), wherein the dispensing process includes a press and breathe type or breath actuated or other multi-step operation medicament dispensers.
The present disclosure relates to a medicament dispenser for dispensing medicament. The dispenser may be for use in dispensing medicament in a liquid, pressurized aerosol, pre- filled container and in any medicament dispenser where dose related feedback is required. Mechanisms and assemblies provide dose related feedback to the user of the medicament dispenser and the physical interfaces and attributes associated with providing such feedback. The present disclosure also relates to dose feedback assemblies that can be adapted to various form factors, various individual components and elements of the container-closure system, and/or various target user interfaces. The dispenser is suited for dispensing propellant based pressurized inhalation aerosols for oral and/or nasal delivery; aqueous or non-aqueous systems for oral and/or nasal delivery; liquid dispensers for nasal delivery, multi-dose pre-filled syringes or pens; or dispensers for intra-muscular or subcutaneous delivery and powders for pulmonary administration and tablets, capsules, pellets or agglomerates for oral administration. The dispenser may dispense a propellant based pressurized inhalation aerosol comprising one or more active pharmaceutical ingredient(s)(API) and optionally, one or more propellant, cosolvent, solubilizer, emulsifier, surfactant, salt, acid and micronized or non-micronized pharmaceutically acceptable carrier(s) and/or excipient(s), wherein the dispensing process includes a press and breathe type or breath actuated or other multi-step operation medicament dispensers.
The present disclosure relates to a medicament dispenser for dispensing medicament. The dispenser may be for use in dispensing medicament in a liquid, pressurized aerosol, pre-filled container and in any medicament dispenser where dose related feedback is required. Mechanisms and assemblies provide dose related feedback to the user of the medicament dispenser and the physical interfaces and attributes associated with providing such feedback. The present disclosure also relates to dose feedback assemblies that can be adapted to various form factors, various individual components and elements of the container-closure system, and/or various target user interfaces. The dispenser is suited for dispensing propellant based pressurized inhalation aerosols for oral and/or nasal delivery; aqueous or non-aqueous systems for oral and/or nasal delivery; liquid dispensers for nasal delivery, multi-dose pre-filled syringes or pens; or dispensers for intra-muscular or subcutaneous delivery and powders for pulmonary administration and tablets, capsules, pellets or agglomerates for oral administration. The dispenser may dispense a propellant based pressurized inhalation aerosol comprising one or more active pharmaceutical ingredient(s)(API) and optionally, one or more propellant, cosolvent, solubilizer, emulsifier, surfactant, salt, acid and micronized or non-micronized pharmaceutically acceptable carrier(s) and/or excipient(s), wherein the dispensing process includes a press and breathe type or breath actuated or other multi-step operation medicament dispensers.
New deuterated analogs of elagolix are provided. The novel deuterated elagolix analogs differ from the only previously disclosed deuterated elagolix analogs in structure based on the exclusion of deuterium at certain sites in the compounds and the inclusion of deuterium at other sites. Also provided are new formulations for deuterated elagolix compounds and methods of using such compounds and formulations in the modification of mammalian physiology and especially in the treatment and prevention of a number of diseases and disorders, including endometriosis-associated pain and uterine fibroid conditions.
The invention relates to a drug delivery system for contraception including a steroidal estrogenic compound, a steroidal progestogenic compound or a combination thereof for the purposes of contraception in a subject, and provides for an ultra-low dose delivery of a steroidal estrogenic compound. The invention also relates to a method of contraception using the drug delivery system and method of manufacturing the drug delivery system.
A61K 31/567 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes non substitués en position 17 bêta par un atome de carbone, p. ex. œstrane, œstradiol substitués en position 17 alpha, p. ex. mestranol, noréthandrolone
A61K 9/02 - SuppositoiresBougiesExcipients pour suppositoires ou bougies
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
49.
DOSE INDICATOR ASSEMBLY FOR A MEDICAMENT DISPENSER
A dose indicator assembly for use with a medicament dispenser, the dose indicator assembly comprising: a dose indicator units wheel having a first count indicia; a dose indicator tens wheel having a second count indicia and a dose indicator notch; and a dose indicator transfer wheel, wherein the first count indicia and second count indicia align at a common viewing area to collectively display a count sequence; and wherein the dose indicator notch engages with a dose indicator stopper stud at the end of the count sequence.
G06M 1/04 - Caractéristiques d'ordre général pour entraîner l'étage du rang le plus bas
G06M 1/06 - Caractéristiques d'ordre général pour entraîner l'étage du rang le plus bas produisant une révolution continue de l'étage, p. ex. avec train d'engrenage
50.
DEUTERATED SECNIDAZOLE FOR USE IN THE TREATMENT OF BACTERIAL VAGINOSIS AND METHODS AND USES THEREOF
The present invention is related to deuterated secnidazole, a prodrug thereof, a hydrate thereof, a solvate thereof, a polymorph thereof, or a pharmaceutically acceptable salt thereof and its use for the treatment of bacterial vaginosis or trichomoniasis in a subject in need thereof. The present invention is also related to pharmaceutical compositions and methods and uses of treating bacterial vaginosis, trichomoniasis, amoebiasis, giardiasis, or a combination thereof.
C07D 233/94 - Radicaux nitro liés en position 4 ou 5 avec des radicaux hydrocarbonés, substitués par des atomes d'oxygène ou de soufre, liés aux autres chaînons du cycle
51.
DEUTERATED SECNIDAZOLE FOR USE IN THE TREATMENT OF BACTERIAL VAGINOSIS AND METHODS AND USES THEREOF
The present invention is related to deuterated secnidazole, a prodrug thereof, a hydrate thereof, a solvate thereof, a polymorph thereof, or a pharmaceutically acceptable salt thereof and its use for the treatment of bacterial vaginosis or trichomoniasis in a subject in need thereof. The present invention is also related to pharmaceutical compositions and methods and uses of treating bacterial vaginosis, trichomoniasis, amoebiasis, giardiasis, or a combination thereof.
C07D 233/94 - Radicaux nitro liés en position 4 ou 5 avec des radicaux hydrocarbonés, substitués par des atomes d'oxygène ou de soufre, liés aux autres chaînons du cycle
52.
SECNIDAZOLE FOR USE IN THE TREATMENT OF BACTERIAL VAGINOSIS
Method of treating bacterial vaginosis in a subject in need thereof involving administering to the subject a therapeutically effective amount of secnidazole in a microgranule formulation, wherein the microgranule formulation comprises a plurality of microgranules having a volume-weighted particle size distribution within a microgranule population, wherein the volume-weighted particle size distribution as measured from a representative sample of the microgranule population comprises (a) 10% of the microgranule population having a volume-weighted particle size about no less than 470 micrometers; (b) 50% of the microgranule population having a volume-weighted particle size between about no less than 640 micrometers and about no more than 810 micrometers; (c) 90% of the microgranule population having a volume-weighted particle size about no more than 1170 micrometers; or (d) a combination thereof, which can include some or all of (a) through (c) above.
The present invention provides a stable pharmaceutical composition to be used with pressurized metered dose inhalers and comprises a β2 agonist, a propellant, a co-solvent, an organic acid(s) and optionally water. The invention further provides stable pharmaceutical composition comprising β2 agonist, an inhaled corticosteroid and/or a long acting muscarinic antagonist. The invention also provides pharmaceutical composition for the treatment or prophylaxis of asthma, chronic obstructive pulmonary disease (COPD), rhinitis or as adjunct therapy for cystic fibrosis, non-cystic fibrosis bronchiectasis, lung infections or pulmonary fibrosis.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/167 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p. ex. lidocaïne, paracétamol
A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
A61P 11/02 - Agents rhinologiques, p. ex. décongestionnants
A medicament dispenser for dispensing medicament comprising: an assembly comprising: at least one peelable medicament carrier carrying multiple distinct medicament portions; a medicament carrier advancing mechanism; a flow channel; and a hinged cover for the flow channel.
A medicament dispenser for dispensing medicament comprising: a diskette assembly (1) comprising: at least one medicament carrier (5) carrying multiple distinct medicament portions; a medicament carrier advancing mechanism for actuating the distinct medicament portions; a flow channel; a lever (2); and an outer cover (3) for said flow channel, wherein the outer cover is adapted to couple with the lever and the medicament carrier advancing mechanism.
Embodiments described herein are directed to novel pharmaceutical compositions comprising a plurality of microgranules comprising nitroimidazole compounds, and uses of these pharmaceutical compositions in the treatment of bacterial vaginosis.
C07D 233/94 - Radicaux nitro liés en position 4 ou 5 avec des radicaux hydrocarbonés, substitués par des atomes d'oxygène ou de soufre, liés aux autres chaînons du cycle
59.
Topical pharmaceutical gel composition of diclofenac sodium
A topical pharmaceutical gel compositions of diclofenac sodium, is provided. The topical gel composition contains at least about 10% w/w diclofenac sodium and is suitable for twice daily application.
A61K 31/196 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p. ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
60.
Topical pharmaceutical gel composition of diclofenac sodium
Topical pharmaceutical gel compositions of diclofenac sodium are provided. The topical gel compositions contain at least about 10% w/w diclofenac sodium and are suitable for once-a-day topical application.
A61K 31/196 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p. ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A topical pharmaceutical gel composition of diclofenac sodium suitable for once-a-day topical application is provided. The topical gel composition contains at least about 10 % w/w of diclofenac sodium and once-a-day application of the composition provides relief from pain or inflammation comparable to that achieved with four times daily application of diclofenac sodium 1 % or 3 % topical gel.
A61K 31/196 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p. ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
Embodiments are directed to a secnidazole formulations and the use of a secnidazole formulation for the treatment of bacterial vaginosis (BV). Embodiments described herein are directed to a method of treating bacterial vaginosis in a subject in need thereof comprising administering to the subject a therapeutically effective amount of secnidazole in a microgranule formulation. In some embodiments, the secnidazole in a microgranule formulation is administered orally. In some embodiments, the secnidazole in a microgranule formulation comprises a plurality of microgranules.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations, namely, for the cleansing of bowel to remove obstruction or to alleviate gastric retention in preparation for a colonoscopy
